

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Mounjaro, Monocef and Zerodol SP Lead Brand Growth in Jan 2026: PHARMARACK

11 February 2026 | News

Lilly's Mounjaro emerged as the top-performing brand for the month



In January 2026, select corporate brands delivered standout growth performances within the Indian Pharmaceutical Market, driven by strong value and volume traction. Eli Lilly's Mounjaro emerged as the top-performing brand for the month, recording the highest sales value of Rs 113 crore, ranking first in monthly sales, reflecting its rapid market uptake, according to PHARMARACK.

Aristo's Monocef posted one of the strongest growth trajectories, registering a sharp 41.6 per cent value growth and an exceptional 37.5 per cent unit growth, with January sales of Rs 56 crore, underscoring robust demand momentum. IPCA's Zerodol SP also delivered a strong performance, reporting 31.2 per cent value growth and 22.4 per cent unit growth, with monthly sales of Rs 67 crore.

Among large, established brands, Cipla's Foracort recorded a solid 18.8 per cent value growth despite a marginal decline in units, achieving Rs 85 crore in January sales, while USV's Glycomet GP posted a healthy 16.6 per cent value growth with sales of Rs 79 crore. Torrent's Cilacar stood out among chronic therapies, delivering 25.5 per cent value growth and 15.2 per cent unit growth, supported by Rs 47 crore in monthly revenues.

Overall, January 2026 performance highlights a strong mix of rapid growth from emerging brands and sustained momentum from established corporate portfolios, with select brands significantly outperforming the broader market on both value and volume growth.